164 related articles for article (PubMed ID: 37345085)
21. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
22. Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?
Dubrava AL; Kyaw PSP; Newman J; Pringle J; Westhuyzen J; La Hera Fuentes G; Shakespeare TP; Sakalkale R; Aherne NJ
Breast Cancer (Dove Med Press); 2023; 15():359-371. PubMed ID: 37197610
[TBL] [Abstract][Full Text] [Related]
23. Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling.
Al-Zahrani KN; Cook DP; Vanderhyden BC; Sabourin LA
Oncotarget; 2018 Sep; 9(70):33348-33359. PubMed ID: 30279965
[TBL] [Abstract][Full Text] [Related]
24. Correlation between Androgen Receptor Expression and Immunohistochemistry Type as Prognostic Factors in a Cohort of Breast Cancer Patients: Result from a Single-Center, Cross Sectional Study.
Niță I; Nițipir C; Toma ȘA; Limbău AM; Pîrvu E; Bădărău IA; Suciu I; Suciu G; Manolescu LSC
Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33802610
[TBL] [Abstract][Full Text] [Related]
25. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
26. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Gillece JD; Folkerts M; Reining L; Highlander SK; Robinson K; Padam S; Martinez N; Tang A; Schmolze D; Waisman J; Sedrak M; Lee PP; Mortimer J
Oncologist; 2021 Feb; 26(2):99-e217. PubMed ID: 33141975
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.
Haruna M; Daramola AO; Awolola NA; Badr NM; Banjo AAF; Shaaban A
Ecancermedicalscience; 2022; 16():1452. PubMed ID: 36405944
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Yardley DA; Young RR; Adelson KB; Silber AL; Najera JE; Daniel DB; Peacock N; Finney L; Hoekstra SJ; Shastry M; Hainsworth JD; Burris HA
Clin Breast Cancer; 2022 Apr; 22(3):269-278. PubMed ID: 34824002
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
Zuo T; Wilson P; Cicek AF; Harigopal M
Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity of triple-negative breast cancer: mammographic, US, and MR imaging features according to androgen receptor expression.
Bae MS; Park SY; Song SE; Kim WH; Lee SH; Han W; Park IA; Noh DY; Moon WK
Eur Radiol; 2015 Feb; 25(2):419-27. PubMed ID: 25224727
[TBL] [Abstract][Full Text] [Related]
34. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
Safarpour D; Tavassoli FA
Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer.
McNamara KM; Yoda T; Miki Y; Nakamura Y; Suzuki T; Nemoto N; Miyashita M; Nishimura R; Arima N; Tamaki K; Ishida T; Ohuchi N; Sasano H
Int J Biol Markers; 2015 May; 30(2):e184-9. PubMed ID: 25588857
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
37. Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer.
Christenson JL; O'Neill KI; Williams MM; Spoelstra NS; Jones KL; Trahan GD; Reese J; Van Patten ET; Elias A; Eisner JR; Richer JK
Mol Cancer Ther; 2021 Jun; 20(6):1062-1071. PubMed ID: 33722849
[TBL] [Abstract][Full Text] [Related]
38. Multi-Parametric MRI-Based Radiomics Models for Predicting Molecular Subtype and Androgen Receptor Expression in Breast Cancer.
Huang Y; Wei L; Hu Y; Shao N; Lin Y; He S; Shi H; Zhang X; Lin Y
Front Oncol; 2021; 11():706733. PubMed ID: 34490107
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
40. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases.
Anders CK; Deal AM; Miller CR; Khorram C; Meng H; Burrows E; Livasy C; Fritchie K; Ewend MG; Perou CM; Carey LA
Cancer; 2011 Apr; 117(8):1602-11. PubMed ID: 21472708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
